-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Intelligent Bio Solutions (INBS) Vs. Its Rivals Head-To-Head Review
Intelligent Bio Solutions (INBS) Vs. Its Rivals Head-To-Head Review
Intelligent Bio Solutions (NASDAQ:INBS – Get Rating) is one of 223 public companies in the "Surgical & medical instruments" industry, but how does it weigh in compared to its rivals? We will compare Intelligent Bio Solutions to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.
Risk & Volatility
Intelligent Bio Solutions has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions' rivals have a beta of 1.37, indicating that their average share price is 37% more volatile than the S&P 500.
Get Intelligent Bio Solutions alerts:Profitability
This table compares Intelligent Bio Solutions and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intelligent Bio Solutions | -1,078.91% | -106.09% | -62.08% |
| Intelligent Bio Solutions Competitors | -1,355.92% | -145.04% | -26.44% |
Insider and Institutional Ownership
2.3% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 45.3% of shares of all "Surgical & medical instruments" companies are owned by institutional investors. 1.9% of Intelligent Bio Solutions shares are owned by insiders. Comparatively, 15.0% of shares of all "Surgical & medical instruments" companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.Analyst Ratings
This is a summary of recent ratings and recommmendations for Intelligent Bio Solutions and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intelligent Bio Solutions | 0 | 0 | 0 | 0 | N/A |
| Intelligent Bio Solutions Competitors | 900 | 3417 | 7595 | 172 | 2.58 |
As a group, "Surgical & medical instruments" companies have a potential upside of 23.20%. Given Intelligent Bio Solutions' rivals higher probable upside, analysts plainly believe Intelligent Bio Solutions has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Intelligent Bio Solutions and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Intelligent Bio Solutions | $440,000.00 | -$8.31 million | -2.12 |
| Intelligent Bio Solutions Competitors | $1.10 billion | $81.57 million | 10.59 |
Intelligent Bio Solutions' rivals have higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Intelligent Bio Solutions rivals beat Intelligent Bio Solutions on 7 of the 10 factors compared.
Intelligent Bio Solutions Company Profile
(Get Rating)
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
Intelligent Bio Solutions (NASDAQ:INBS – Get Rating) is one of 223 public companies in the "Surgical & medical instruments" industry, but how does it weigh in compared to its rivals? We will compare Intelligent Bio Solutions to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.
智能生物解决方案公司(纳斯达克代码：INBS-GET Rating)是“外科医疗器械”行业223家上市公司之一，但与竞争对手相比，它在其中的权重如何？我们将根据其估值、盈利能力、分析师建议、机构所有权、股息、风险和收益的优势，将智能生物解决方案与类似业务进行比较。
Risk & Volatility
风险与波动性
Intelligent Bio Solutions has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions' rivals have a beta of 1.37, indicating that their average share price is 37% more volatile than the S&P 500.
Intelligence Bio Solutions的贝塔系数为1.48，这表明其股价的波动性比标准普尔500指数高48%。相比之下，智能生物解决方案的竞争对手的贝塔系数为1.37，这表明它们的平均股价波动性比标准普尔500指数高37%。
Profitability
盈利能力
This table compares Intelligent Bio Solutions and its rivals' net margins, return on equity and return on assets.
此表比较了智能生物解决方案及其竞争对手的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Intelligent Bio Solutions | -1,078.91% | -106.09% | -62.08% |
| Intelligent Bio Solutions Competitors | -1,355.92% | -145.04% | -26.44% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 智能生物解决方案 | -1,078.91% | -106.09% | -62.08% |
| 智能生物解决方案竞争对手 | -1,355.92% | -145.04% | -26.44% |
Insider and Institutional Ownership
内部人与机构持股
Analyst Ratings
分析师评级
This is a summary of recent ratings and recommmendations for Intelligent Bio Solutions and its rivals, as provided by MarketBeat.com.
这是对智能生物解决方案及其竞争对手最近的评级和推荐的摘要，由MarketBeat.com提供。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intelligent Bio Solutions | 0 | 0 | 0 | 0 | N/A |
| Intelligent Bio Solutions Competitors | 900 | 3417 | 7595 | 172 | 2.58 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 智能生物解决方案 | 0 | 0 | 0 | 0 | 不适用 |
| 智能生物解决方案竞争对手 | 900 | 3417 | 7595 | 172 | 2.58 |
As a group, "Surgical & medical instruments" companies have a potential upside of 23.20%. Given Intelligent Bio Solutions' rivals higher probable upside, analysts plainly believe Intelligent Bio Solutions has less favorable growth aspects than its rivals.
作为一个整体，“外科和医疗器械”公司有23.20%的潜在上行空间。考虑到智能生物解决方案的竞争对手更有可能上行，分析师显然认为智能生物解决方案的增长方面不如竞争对手有利。
Earnings and Valuation
收益和估值
This table compares Intelligent Bio Solutions and its rivals top-line revenue, earnings per share and valuation.
此表比较了智能生物解决方案及其竞争对手的营收、每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Intelligent Bio Solutions | $440,000.00 | -$8.31 million | -2.12 |
| Intelligent Bio Solutions Competitors | $1.10 billion | $81.57 million | 10.59 |
| 总收入 | 净收入 | 市盈率 | |
| 智能生物解决方案 | $440,000.00 | -831万元 | -2.12 |
| 智能生物解决方案竞争对手 | 11.亿美元 | 8157万美元 | 10.59 |
Intelligent Bio Solutions' rivals have higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
智能生物解决方案的竞争对手比智能生物解决方案的收入和收益更高。智能生物解决方案的市盈率低于竞争对手，这表明它目前比行业内的其他公司更实惠。
Summary
摘要
Intelligent Bio Solutions rivals beat Intelligent Bio Solutions on 7 of the 10 factors compared.
在比较的10个因素中，智能生物解决方案的竞争对手在7个方面击败了智能生物解决方案。
Intelligent Bio Solutions Company Profile
智能生物解决方案公司简介
(Get Rating)
(获取评级)
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
智能生物解决方案公司是一家生命科学公司，为患者及其初级健康从业者开发非侵入性、实时监测和诊断测试。它提供唾液葡萄糖生物传感器，这是一种用于糖尿病治疗的有机薄膜晶体管，可以测量唾液中的葡萄糖。该公司还专注于开发SARS-CoV-2生物传感器，生物传感器测试可作为(RNA)病毒检测测试的补充；以及一个由生物化学、免疫学、肿瘤标志物、激素和核酸诊断模式组成的生物传感器平台。该公司前身为GBS Inc.，并于2022年10月更名为Intelligence Bio Solutions Inc.。该公司成立于2016年，总部设在纽约。智能生物解决方案公司是生命科学生物传感器诊断有限公司的子公司。
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到智能生物解决方案的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对智能生物解决方案和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧